Gyeonggi-do, South Korea

Gil-Jung Kim

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Innovator Spotlight: Gil-Jung Kim**

Introduction

Gil-Jung Kim is an accomplished inventor based in Gyeonggi-do, South Korea. With a focus on advanced biomedical research, he has made significant contributions to the field of antibody development.

Latest Patents

Gil-Jung Kim holds a patent for an innovative "Antibody library and antibody screening method using same." This invention is centered around a novel antibody library that leverages a human sequence-derived specific VH or VL scaffold. The unique features of this antibody library include high thermodynamic stability and the ability to facilitate high soluble expression and reversible folding. Furthermore, the antibodies produced through this method possess various rationally controlled CDRs, enabling them to demonstrate high specificity and affinity towards multiple antigens. This technology has the potential to be significantly advantageous in selecting suitable candidate antibodies against targeted antigens.

Career Highlights

Kim is affiliated with the Mogam Institute for Biomedical Research, which is dedicated to advancing scientific knowledge and innovations in biomedical fields. His research and invention illustrate his commitment to enhancing the capabilities of antibody technologies.

Collaborations

Throughout his career, Gil-Jung Kim has likely engaged in collaborative efforts with fellow researchers and institutions, although specific details on his collaborations are not provided.

Conclusion

Gil-Jung Kim’s contribution to the field of antibody development exemplifies the potential of innovative research in providing solutions for biomedical challenges. His unique patent and the work he is undertaking at the Mogam Institute for Biomedical Research may pave the way for future advancements in the selection and application of antibodies in therapeutic settings.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…